Denali Therapeutics Inc (DNLI) — Cash Flow Reinvestment Rate
Denali Therapeutics Inc (DNLI) has a Cash Flow Reinvestment Rate of 0.71x as of December 2020, reinvesting $367.34 Million (capex $1.19 Million plus investments $-366.14 Million) from operating cash flow of $513.91 Million. See DNLI FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Denali Therapeutics Inc Cash Flow Reinvestment Rate (2018–2020)
Historical reinvestment intensity for Denali Therapeutics Inc across 2 annual periods. For the full cash flow conversion analysis, see Denali Therapeutics Inc (DNLI) cash flow conversion.
Annual Cash Flow Reinvestment Rate for Denali Therapeutics Inc (2018–2020)
Year-by-year capital reinvestment analysis for Denali Therapeutics Inc. See DNLI financial flexibility score to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (USD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2020 | 1.50x | $623.21 Million | $416.15 Million | $3.10 Million | ▼ -73.9% |
| 2018 | 5.74x | $287.42 Million | $50.12 Million | $3.39 Million | — |